NHS Offers First Drug Targeting Advanced Breast Cancers Driven by BRCA Gene Mutations

Talazoparib will become the NHS’s first targeted treatment for advanced breast cancers caused by mutations to BRCA genes, after a recommendation by the National Institute for Health and Care Excellence.